"Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors. The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs."
"That includes a more than 40% cut for Boehringer Ingelheim's diabetes drug Jardiance and three related treatments. Boehringer Ingelheim and Eli Lilly, which sell Jardiance together, did not immediately respond to requests for comment on the reason for the price cuts. Jardiance is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026."
Drugmakers plan U.S. list price increases on at least 350 branded medicines for 2026, up from more than 250 at the same point last year, with a median hike near 4%. The listed increases exclude rebates to pharmacy benefit managers and other discounts. Manufacturers also announced roughly nine list-price cuts, including a more than 40% reduction for Jardiance and three related drugs. The U.S. government negotiated lower Medicare prices for ten drugs, prompting a two-thirds Jardiance reduction for older beneficiaries. The administration has secured pricing deals with some manufacturers, yet several of those companies still plan January 1 price increases.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]